Get the Stockscreener App
1.23
4.65%
-0.06
After Hours:
1.24
0.01
+0.81%
Milestone Pharmaceuticals Inc stock is traded at $1.23, with a volume of 2.41M.
It is down -4.65% in the last 24 hours and down -34.57% over the past month.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
See More
Previous Close:
$1.29
Open:
$1.28
24h Volume:
2.41M
Relative Volume:
1.22
Market Cap:
$153.13M
Revenue:
$1.55M
Net Income/Loss:
$-63.06M
P/E Ratio:
-1.5454
EPS:
-0.7959
Net Cash Flow:
$-49.45M
1W Performance:
-13.38%
1M Performance:
-34.57%
6M Performance:
-54.10%
1Y Performance:
-29.31%
1-Day Range:
$1.21
$1.28
1-Week Range:
$1.21
$1.435
52-Week Range:
$1.00
$3.06
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Name
Milestone Pharmaceuticals Inc
Sector
Industry
Phone
(514) 336-0444
Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.23 | 160.60M | 1.55M | -63.06M | -49.45M | -0.7959 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Strong Buy |
| Dec-15-25 | Upgrade | TD Cowen | Hold → Buy |
| Sep-11-25 | Initiated | Wells Fargo | Overweight |
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-20-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-22-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-05-21 | Initiated | H.C. Wainwright | Buy |
| Jul-29-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-24-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-25-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-24-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-24-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-04-19 | Initiated | Oppenheimer | Outperform |
| Jun-03-19 | Initiated | Cowen | Outperform |
| Jun-03-19 | Initiated | Jefferies | Buy |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Milestone Pharmaceuticals Inc Stock (MIST) Latest News
Novartis Canada and the pan-Canadian Pharmaceutical Alliance Achieve Milestone Agreement Enabling Public Reimbursement of (pr)Scemblix® (asciminib tablets) - Newswire Canada
Milestone Pharmaceuticals: Taking The Long View (NASDAQ:MIST) - Seeking Alpha
MIST Technical Analysis | Trend, Signals & Chart Patterns | MILESTONE PHARMACEUTICALS IN (NASDAQ:MIST) - ChartMill
Eli Lilly scores a first in major pharma milestone - thestreet.com
Heart Rhythm Society and Milestone Pharmaceuticals Partner to Expand SVT Patient Education Through UpBeat.org - PR Newswire
Wockhardt's Zaynich wins US FDA approval, marking milestone in antibiotic innovation - Business Today
Milestone (MIST) Q1 2026 Earnings Transcript - The Globe and Mail
Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum - PR Newswire
Analysts Offer Insights on Healthcare Companies: Alpha Tau Medical Ltd (DRTS), Neurogene (NGNE) and Milestone Pharmaceuticals (MIST) - The Globe and Mail
[EFFECT] Milestone Pharmaceuticals Inc. SEC Filing - Stock Titan
Milestone Pharmaceuticals (MIST) Slides 7.24% as Selling Pressure Builds—Key Support at $1.34 in FocusOBV Divergence - thelegaladvocate.com
Milestone Pharmaceuticals Q1 earnings call highlights - MSN
MIST Stock Price, Quote & Chart | MILESTONE PHARMACEUTICALS IN (NASDAQ:MIST) - ChartMill
Supernus Pharmaceuticals to make $33.4 million CVR milestone payment - Investing.com
Milestone reports Q1 results, highlights initial CARDAMYST sales - MSN
Milestone Pharmaceuticals Q1 2026 earnings preview - MSN
Milestone outlines ~2-year phase III AFib-RVR timeline as CARDAMYST launch reaches ~600 prescriptions - MSN
Milestone Pharmaceuticals (MIST) reports Q1 loss, lags revenue estimates - MSN
RTW Investments (MIST) and Roderick Wong disclose 9.99% ownership - Stock Titan
Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Path To Profitability - Yahoo Finance
Milestone Pharmaceuticals Inc. (NASDAQ:MIST): Is Breakeven Near? - simplywall.st
MIST Maintained by Wells Fargo -- Price Target Lowered to $7.00 - GuruFocus
Milestone Pharmaceuticals Is Maintained at Overweight by Wells Fargo - Moomoo
Wells Fargo & Company Issues Pessimistic Forecast for Milestone Pharmaceuticals (NASDAQ:MIST) Stock Price - MarketBeat
Milestone Pharmaceuticals Inc.Common Shares (NQ: MIST - FinancialContent
Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - The Manila Times
NASDAQ fireside chat: Milestone talks cardiovascular drugs on May 19 - Stock Titan
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Q1 2026 Earnings Call Transcript - Insider Monkey
Piper Sandler Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Raises Target Price to $7 - Moomoo
Milestone Pharmaceuticals Inc. Q1 2026 10-Q Report: Financial Statements, Risk Factors, and Forward-Looking Statements - Minichart
TD Cowen Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Milestone Pharmaceuticals Inc (MIST) Q1 2026 Earnings Call Highl - GuruFocus
Milestone Pharmaceuticals Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Milestone Pharmaceuticals Files $300 Million Mixed Shelf - Moomoo
Why Milestone Pharmaceuticals stock wilted on Wednesday - MSN
Why Milestone Pharmaceuticals Stock Wilted on Wednesday - The Motley Fool
Milestone Pharmaceuticals Inc. Stock 12‑Month Price Target Cut to $6.33, Implies 233% Upside - TradingView
According to documents submitted to the U.S. Securities and Exchange Commission (SEC), Milestone Pharmaceuticals Inc. may issue and sell common shares worth up to 100 million dollars through an equity distribution sales agreement with Cantor Fitzgeral - Bitget
Milestone Pharmaceuticals IncMay offer securities up to $300 millionSEC filing - marketscreener.com
Milestone Pharmaceuticals (NASDAQ: MIST) files $300M shelf; $100M ATM with Cantor Fitzgerald - Stock Titan
Q1 2026 Milestone Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
H.C. Wainwright Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Milestone Pharmaceuticals (NASDAQ:MIST) Issues Earnings Results - MarketBeat
Milestone Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
Milestone Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
Milestone Pharmaceuticals (MIST) Reports Q1 Earnings Miss - GuruFocus
Milestone Pharmaceuticals (MIST) Q1 2026 Earnings: EPS and Reven - GuruFocus
Milestone Pharmaceuticals (MIST) Reports Strong Q1 Revenue Growt - GuruFocus
Milestone Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Milestone Pharmaceuticals Q1 2026 misses forecasts, stock drops - Investing.com Nigeria
Milestone Pharmaceuticals Inc Stock (MIST) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):